Search

Search
Generic filters
Pfizer completes acquisition of Global Blood Therapeutics

Pfizer completes acquisition of Global Blood Therapeutics

Pfizer Inc. (NYSE: PFE) announced the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities starting with sickle cell disease (SCD).
Making pharmacy more sustainable

Making pharmacy more sustainable

In the article published in the prestigious scientific journal Science, a group of international researchers, including Gorka Orive, Doctor of Pharmacy and researcher in the UPV/EHU’s NanoBioCel group, and Unax Lertxundi of the Bioaraba Institute for Health Research, have issued a warning about the increase in pharmaceutical contamination.
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities

Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need. Fast Track designation is intended to bring promising medicines to patients sooner.
Repurposing existing drugs to fight new COVID-19 variants

Repurposing existing drugs to fight new COVID-19 variants

Michigan State University (MSU) researchers are using big data and AI to identify current drugs that could be applied to treat new COVID-19 variants.

Finding new ways to treat the novel coronavirus and its ever-changing variants has been a challenge for researchers, especially when the traditional drug development and discovery process can take years.

Discovering new cancer treatments in the “dark matter” of the human genome

Discovering new cancer treatments in the “dark matter” of the human genome

Cancer is in Switzerland the second leading cause of death. Among the different types of cancers, non-small cell lung cancer (NSCLC) kills the most patients and remains largely incurable. Unfortunately, even newly approved therapies can extend the life of patients only by a few months and only few survive the metastatic stadium long-term.
Pfizer completes acquisition of Biohaven Pharmaceuticals

Pfizer completes acquisition of Biohaven Pharmaceuticals

Pfizer Inc. (NYSE: PFE) announced the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
Another monkey virus could be poised for spillover to humans

Another monkey virus could be poised for spillover to humans

An obscure family of viruses, already endemic in wild African primates and known to cause fatal Ebola-like symptoms in some monkeys, is “poised for spillover” to humans, according to new University of Colorado Boulder research published online Sept. 30 in the journal Cell.
The Nobel Prize in Physiology or Medicine 2022

The Nobel Prize in Physiology or Medicine 2022

The Nobel Assembly at Karolinska Institutet has today decided to award the 2022 Nobel Prize in Physiology or Medicine to Svante Pääbo for his discoveries concerning the genomes of extinct hominins and human evolution.

Non-opioid compounds squelch pain without sedation

Non-opioid compounds squelch pain without sedation

A newly identified set of molecules alleviated pain in mice while avoiding the sedating affect that limits the use of opiates, according to a new study led by researchers at UC San Francisco. The molecules act on the same receptor as clonidine and dexmedetomidine – drugs commonly used in hospitals as sedatives – but are chemically unrelated to them and may not be addictive.
Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19

Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19

AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19.
Back to Top
Product has been added to your cart